» Articles » PMID: 36016661

Predictive Value of Nasal Nitric Oxide and Serum NOS2 Levels in the Efficacy of Subcutaneous Immunotherapy in Pediatric Patients with Allergic Rhinitis

Overview
Publisher Wiley
Specialties Biochemistry
Pathology
Date 2022 Aug 26
PMID 36016661
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Subcutaneous immunotherapy (SCIT) is an effective therapy for allergic rhinitis (AR), but some AR patients still do not benefit from it. Nasal nitric oxide (nNO) and inducible nitric oxide synthase (iNOS/NOS2) act important roles in AR. This study aims to explore the abilities of serum NOS2 and nNO in predicting the clinical efficacy of SCIT in AR patients.

Methods: We recruited 40 healthy controls (HCs) and 120 AR patients in this study. Serum NOS2 and nNO levels were compared between the two groups. In the AR group, patients underwent and finished 1-year of SCIT, and divided into the effective and ineffective groups, and the relationships between serum NOS2 and nNO levels and efficacy of SCIT were evaluated.

Results: The serum NOS2 and nNO levels were higher in AR patients than HCs. In the effective group, the serum NOS2 and nNO levels were increased than the ineffective group. ROC curves presented that a combination of serum NOS2 and nNO exhibited promising predictive ability in predicting the clinical efficacy of SCIT.

Conclusions: Serum NOS2 and nNO levels were enhanced in AR patients and might affect the efficacy of SCIT. The combined use of serum NOS2 and nNO levels could be a reliable and useful method for predicting the clinical efficacy of SCIT.

Citing Articles

Nasal nitric oxide measurement in allergic rhinitis and non-allergic rhinitis: a meta-analysis.

Dahlan A, Islam M, Md Shukri N, Abdullah B Acta Otorhinolaryngol Ital. 2024; 44(2):100-112.

PMID: 38651552 PMC: 11042547. DOI: 10.14639/0392-100X-N2634.


Role of Nasal Nitric Oxide in Primary Ciliary Dyskinesia and Other Respiratory Conditions in Children.

Paterno S, Pisani L, Zanconato S, Ferraro V, Carraro S Int J Mol Sci. 2023; 24(22).

PMID: 38003348 PMC: 10671569. DOI: 10.3390/ijms242216159.


Correlation of serum HMGB1 and HMGB2 levels with clinical symptoms in allergic rhinitis children.

Xing X, Wang H Medicine (Baltimore). 2023; 102(37):e34921.

PMID: 37713866 PMC: 10508371. DOI: 10.1097/MD.0000000000034921.


Clinical Applications of Nasal Nitric Oxide in Allergic Rhinitis: A Review of the Literature.

Marcuccio G, Ambrosino P, Merola C, Manzo F, Motta A, Rea G J Clin Med. 2023; 12(15).

PMID: 37568482 PMC: 10420175. DOI: 10.3390/jcm12155081.

References
1.
Bousquet J, Hellings P, Agache I, Amat F, Annesi-Maesano I, Ansotegui I . Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2018; 143(3):864-879. DOI: 10.1016/j.jaci.2018.08.049. View

2.
Li Y, Wang Y, Zhang Q . [Expression of cell adhesion molecule and nitric oxide synthase in nasal mucosa in allergic rhinitis]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006; 20(7):315-8. View

3.
Garzorz N, Eyerich K . NOS2 and CCL27: clinical implications for psoriasis and eczema diagnosis and management. Expert Rev Clin Immunol. 2014; 11(2):167-9. DOI: 10.1586/1744666X.2015.996549. View

4.
Brozek J, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4):950-958. DOI: 10.1016/j.jaci.2017.03.050. View

5.
Zhang Y, Lan F, Zhang L . Advances and highlights in allergic rhinitis. Allergy. 2021; 76(11):3383-3389. DOI: 10.1111/all.15044. View